TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomes SM-88 is an oral, investigational cancer metabolism-based therapy that has demonstrated confirmed clinical responses… Read More
SCOTTSDALE, Ariz., Sept. 12, 2019, /PRNewswire/ -- Imaging Endpoints (IE) has announced the opening of its new corporate headquarters in Scottsdale, Arizona to accommodate the company's tremendous growth. The company also has an office in Waltham, Massachusetts as well as… Read More
Summary Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ~50% of metastatic MM patients developing brain metastases (BM). Targeted therapies and immune checkpoint inhibitors have improved overall survival for MM patients with BM. However, responses… Read More
Archival tumor samples represent a rich resource of annotated specimens for translational genomics research. However, standard variant calling approaches require a matched normal sample from the same individual, which is often not available in the retrospective setting, making it difficult… Read More
Abstract Pancreas cancer is an aggressive and fatal disease that will become one of the leading causes of cancer mortality by 2030. An all-out effort is underway to better understand the basic biologic mechanisms of this disease ranging from early… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
